Thus, we describe a novel role of ISCA2 in HIF and iron regulation and highlight its value as a potential therapeutic target in ccRCC for the dual inhibition of HIF-α and the induction of ferroptosis. Here, ISCA2 is linked to nonpapillary renal cell carcinoma.